Zobrazeno 1 - 10
of 47
pro vyhledávání: '"A. W. Gotta"'
Publikováno v:
Ophthalmology Clinics of North America. 11:11-23
The local anesthetics are widely used, safe, effective drugs, capable of relieving pain, making surgery possible, and yet, at the same time, possess a high index of safety. To use these substances to their greatest advantage, and with minimal risk of
Publikováno v:
Anesthesiology Clinics of North America. 14:13-28
Traumatic disruption of the bony, cartilaginous, and soft-tissue components of the airway may be so severe and so apparent as to make it obvious that, indeed, the airway is compromised, and adequate ventilation is jeopardized. Contrariwise, apparentl
Autor:
Alexander W. Gotta
Publikováno v:
Anesthesiology Clinics of North America. 14:1-12
Trauma is an integral part of human existence. From the time that Cain slew Abel, humans have learned that the most effective way to end a disagreement and silence an opponent is to bring the controversy to a traumatic ending, quieting rancor and ang
Autor:
Alexander W. Gotta
Publikováno v:
Current Opinion in Anaesthesiology. 5:420-424
Autor:
Alexander W. Gotta
Publikováno v:
Anesthesiology Clinics of North America. 8:881-895
Summary HIV infection is widely prevalent and the infected patient may present with varied and protean signs and symptoms. Opportunistic infections of the airway, lungs, and central and peripheral nervous systems challenge the anesthesiologist to dev
Autor:
A W, Gotta
Publikováno v:
IDrugs : the investigational drugs journal. 4(3)
Autor:
A W, Gotta
Publikováno v:
IDrugs : the investigational drugs journal. 4(8)
Pharmacia (formerly Monsanto) is developing parecoxib, an injectable COX-2 inhibitor, for the management of post-surgical acute pain [287279], [313957]. By January 1999, the compound was in phase III trials for this indication [312280]. In October 20
Autor:
Alexander W, Gotta
Publikováno v:
Current opinion in investigational drugs (London, England : 2000). 3(2)
Pharmacia (formerly Searle), in collaboration with Pfizer and Yamanouchi, has developed valdecoxib, a second-generation cyclooxygenase (COX)-2 inhibitor as a follow-up to celecoxib, for the treatment of arthritis. Pharmacia filed an NDA with the FDA
Publikováno v:
Anesthesiology. 72:230-232
The onset of akinesia of the extraocular muscles was assessed after peribulbar block with a plain or pH-adjusted solution of 0.75% bupivacaine and hyaluronidase. Thirty-five patients were randomly assigned to receive either 0.75% bupivacaine with hya
Autor:
A. W. Gotta
Publikováno v:
JAMA: The Journal of the American Medical Association. 291:2022-2023